skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial

Abstract

Purpose: To perform a randomized trial comparing 70 and 80 Gy radiotherapy for prostate cancer. Patients and Methods: A total of 306 patients with localized prostate cancer were randomized. No androgen deprivation was allowed. The primary endpoint was biochemical relapse according to the modified 1997-American Society for Therapeutic Radiology and Oncology and Phoenix definitions. Toxicity was graded using the Radiation Therapy Oncology Group 1991 criteria and the late effects on normal tissues-subjective, objective, management, analytic scales (LENT-SOMA) scales. The patients' quality of life was scored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item cancer-specific and 25-item prostate-specific modules. Results: The median follow-up was 61 months. According to the 1997-American Society for Therapeutic Radiology and Oncology definition, the 5-year biochemical relapse rate was 39% and 28% in the 70- and 80-Gy arms, respectively (p = .036). Using the Phoenix definition, the 5-year biochemical relapse rate was 32% and 23.5%, respectively (p = .09). The subgroup analysis showed a better biochemical outcome for the higher dose group with an initial prostate-specific antigen level >15 ng/mL. At the last follow-up date, 26 patients had died, 10 of their disease and none of toxicity, with no differencesmore » between the two arms. According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively. The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046). Similar results were observed using the LENT-SOMA scale. Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039). The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms. Conclusion: High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [7];  [8];  [9];  [10];  [11];  [12];  [13];  [14];  [15];  [16];  [17];  [18];  [1];  [4]
  1. Centre Alexis Vautrin, Vandoeuvre les Nancy (France)
  2. Centre Hospitalier Universitaire, Poitiers (France)
  3. Centre Eugene Marquis, Rennes (France)
  4. Institut Curie, Paris (France)
  5. Hopital Bretonneau Tours (France)
  6. Institut Sainte-Catherine, Avignon (France)
  7. Institut Paoli-Calmette, Marseille (France)
  8. Centre Hospitalier Lyon-Sud, Pierre-Benite (France)
  9. Centre Rene Gauducheau, Saint Herblain (France)
  10. Centre Claudius Regaud, Toulouse (France)
  11. Centre George-Francois Leclerc, Dijon (France)
  12. Centre Antoine Lacassagne, Nice (France)
  13. La Chaussee Saint Victor (France)
  14. Hopital de la Pitie-Salpetriere, Paris (France)
  15. Centre Leon Berard, Lyon (France)
  16. Centre Val D'Aurelle, Montpellier (France)
  17. Centre Henri Becquerel, Rouen (France)
  18. Hopital Henri-Mondor, Creteil (France)
Publication Date:
OSTI Identifier:
21587628
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 80; Journal Issue: 4; Other Information: DOI: 10.1016/j.ijrobp.2010.03.049; PII: S0360-3016(10)00612-7; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANDROGENS; ANTIGENS; BLADDER; NEOPLASMS; PROSTATE; RADIATION DOSES; RADIOTHERAPY; RECTUM; TOXICITY; ANDROSTANES; BODY; DIGESTIVE SYSTEM; DISEASES; DOSES; GASTROINTESTINAL TRACT; GLANDS; HORMONES; INTESTINES; LARGE INTESTINE; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANS; RADIOLOGY; STEROID HORMONES; STEROIDS; THERAPY; URINARY TRACT

Citation Formats

Beckendorf, Veronique, E-mail: v.beckendorf@nancy.fnclcc.fr, Guerif, Stephane, Le Prise, Elisabeth, Cosset, Jean-Marc, Bougnoux, Agnes, Chauvet, Bruno, Salem, Naji, Chapet, Olivier, Bourdain, Sylvain, Bachaud, Jean-Marc, Maingon, Philippe, Hannoun-Levi, Jean-Michel, Malissard, Luc, Simon, Jean-Marc, Pommier, Pascal, Hay, Men, Dubray, Bernard, Lagrange, Jean-Leon, Luporsi, Elisabeth, and Bey, Pierre. 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial. United States: N. p., 2011. Web. doi:10.1016/j.ijrobp.2010.03.049.
Beckendorf, Veronique, E-mail: v.beckendorf@nancy.fnclcc.fr, Guerif, Stephane, Le Prise, Elisabeth, Cosset, Jean-Marc, Bougnoux, Agnes, Chauvet, Bruno, Salem, Naji, Chapet, Olivier, Bourdain, Sylvain, Bachaud, Jean-Marc, Maingon, Philippe, Hannoun-Levi, Jean-Michel, Malissard, Luc, Simon, Jean-Marc, Pommier, Pascal, Hay, Men, Dubray, Bernard, Lagrange, Jean-Leon, Luporsi, Elisabeth, & Bey, Pierre. 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial. United States. doi:10.1016/j.ijrobp.2010.03.049.
Beckendorf, Veronique, E-mail: v.beckendorf@nancy.fnclcc.fr, Guerif, Stephane, Le Prise, Elisabeth, Cosset, Jean-Marc, Bougnoux, Agnes, Chauvet, Bruno, Salem, Naji, Chapet, Olivier, Bourdain, Sylvain, Bachaud, Jean-Marc, Maingon, Philippe, Hannoun-Levi, Jean-Michel, Malissard, Luc, Simon, Jean-Marc, Pommier, Pascal, Hay, Men, Dubray, Bernard, Lagrange, Jean-Leon, Luporsi, Elisabeth, and Bey, Pierre. Fri . "70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial". United States. doi:10.1016/j.ijrobp.2010.03.049.
@article{osti_21587628,
title = {70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial;Prostate cancer; Dose escalation; Conformal radiotherapy; Randomized trial},
author = {Beckendorf, Veronique, E-mail: v.beckendorf@nancy.fnclcc.fr and Guerif, Stephane and Le Prise, Elisabeth and Cosset, Jean-Marc and Bougnoux, Agnes and Chauvet, Bruno and Salem, Naji and Chapet, Olivier and Bourdain, Sylvain and Bachaud, Jean-Marc and Maingon, Philippe and Hannoun-Levi, Jean-Michel and Malissard, Luc and Simon, Jean-Marc and Pommier, Pascal and Hay, Men and Dubray, Bernard and Lagrange, Jean-Leon and Luporsi, Elisabeth and Bey, Pierre},
abstractNote = {Purpose: To perform a randomized trial comparing 70 and 80 Gy radiotherapy for prostate cancer. Patients and Methods: A total of 306 patients with localized prostate cancer were randomized. No androgen deprivation was allowed. The primary endpoint was biochemical relapse according to the modified 1997-American Society for Therapeutic Radiology and Oncology and Phoenix definitions. Toxicity was graded using the Radiation Therapy Oncology Group 1991 criteria and the late effects on normal tissues-subjective, objective, management, analytic scales (LENT-SOMA) scales. The patients' quality of life was scored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item cancer-specific and 25-item prostate-specific modules. Results: The median follow-up was 61 months. According to the 1997-American Society for Therapeutic Radiology and Oncology definition, the 5-year biochemical relapse rate was 39% and 28% in the 70- and 80-Gy arms, respectively (p = .036). Using the Phoenix definition, the 5-year biochemical relapse rate was 32% and 23.5%, respectively (p = .09). The subgroup analysis showed a better biochemical outcome for the higher dose group with an initial prostate-specific antigen level >15 ng/mL. At the last follow-up date, 26 patients had died, 10 of their disease and none of toxicity, with no differences between the two arms. According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively. The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046). Similar results were observed using the LENT-SOMA scale. Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039). The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms. Conclusion: High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity.},
doi = {10.1016/j.ijrobp.2010.03.049},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 4,
volume = 80,
place = {United States},
year = {2011},
month = {7}
}